A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5-fluorouracil. A regimen associated with major toxicity in patients with advanced non-small lung cancer. European Lung Cancer Working Party.
OBJECTIVE
To determine in patients with advanced non-small cell lung cancer the activity of a 4-drug combination chemotherapy.


METHODS
Chemotherapy consisted of the administration of cisplatin (30 mg/m2 d 1-3 or 4), mitomycin C (10 mg/m2 d 1), vindesine (3 mg/m2 d 1) and 5-FU (1 g/m2 d 1-3 or 4 by continuous intravenous infusion.


RESULTS
182 were eligible patients. A 34% objective response rate was observed in the 164 evaluable patients. The overall median survival was 26 weeks. The most serious adverse event was the occurrence of 18 (10%) cardiac or sudden deaths. These toxic deaths were significantly associated with a > or = 5% loss of body weight prior to therapy.


CONCLUSIONS
The regimen studied resulted in a very significant cardiac toxicity.
Klastersky
J
J
Sculier
J P
JP
Ries
F
F
Dabouis
G
G
Libert
P
P
Schmerber
J
J
Thiriaux
J
J
Berchier
M C
MC
Bureau
G
G
Van Cutsem
O
O
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D016757:Death, Sudden, Cardiac / Q000209:etiology; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006321:Heart / Q000187:drug effects; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008937:Mitomycins / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction; D015996:Survival Rate; D014751:Vindesine / Q000008:administration & dosage / Q000009:adverse effects
D008937:Mitomycins; D002945:Cisplatin; D014751:Vindesine; D005472:Fluorouracil